At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.

GlaxoSmithKline Chairman Sir Philip Hampton will step down from his role ahead of the company’s plan to split into two separate business units.

Merck received FDA approval for new indications for the PARP inhibitor Lynparza – which is jointly developed and commercialized by AstraZeneca – and the checkpoint inhibitor Keytruda.

GlaxoSmithKline agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharma business by new Chief Executive Emma Walmsley that unnerved investors.

Magnolia Neurosciences, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.

AstraZeneca’s oncology business received a boost as results of a clinical trial showed the company’s drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

Clovis Oncology Inc. today announced that the European Commission authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.

AstraZeneca and Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending a marketing authorization of Lynparza (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.

AstraZeneca saw revenues and product sales fall over the course of 2017. Total revenues declined 2 percent to $22.46 billion and product sales fell 5 percent to $20.15 billion.

AstraZeneca and Merck announced that the Japanese Ministry of Health, Labour and Welfare approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.